Dataset Information

Prognostic Values of TIM-3 Expression in Patients With Solid Tumors: A Meta-Analysis and Database Evaluation.

ABSTRACT: Background: T cell immunoglobulin and mucin-domain containing molecule-3 (TIM-3), a novel emerging immune checkpoint molecule, was reported to express both on various kinds of immune cells and tumor cells. Many previous studies have investigated the prognostic significance of TIM-3 in cancer. However, the sample number from single study was limited and results remained controversial. Methods: We searched PubMed, Web of Science, and Embase databases for publications concerning TIM-3 expression in solid cancers up to March 2020. The correlations between TIM-3 and survival as well as clinical-pathological features were analyzed. Pooled hazard ratios (HRs), odds ratios (ORs), and 95% confidence interval (CI) were estimated by either fixed or random effects models. Results: A total of 3,072 patients were included in our meta-analysis. The result suggested that TIM-3 protein overexpression was relevant to poor overall survival (HR = 1.73, 95% CI = 1.39-2.15, P < 0.001). Moreover, TIM-3 was shown to be connected with lymph node metastasis (N+ vs. N-, OR = 1.59, 95% CI = 1.10-2.29, P = 0.013), tumor grade (G2-3 vs. G1, OR = 1.68, 95% CI = 1.21-2.34, P = 0.002), as well as PD-1 expression (PD-1high vs. PD-1low, OR = 3.26, 95% CI = 2.20-4.82, P < 0.001). In database test, significant correlations between high TIM-3 mRNA expression and poor overall survival for patients with non-small cell lung cancer and gastric cancer were observed (HR = 1.46, 95% CI = 1.23-1.72, P < 0.001; HR = 1.41, 95% CI = 1.12-1.77, P = 0.0038). Conclusion: Our meta-analysis highlights that TIM-3 has the potential to serve as a prognostic marker and a valuable therapeutic target in solid tumors.

SUBMITTER: Qin S

PROVIDER: S-EPMC7417611 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Prognostic Values of TIM-3 Expression in Patients With Solid Tumors: A Meta-Analysis and Database Evaluation.

Qin Shuang S Dong Bing B Yi Ming M Chu Qian Q Wu Kongming K

Frontiers in oncology 20200804

<b>Background:</b> T cell immunoglobulin and mucin-domain containing molecule-3 (TIM-3), a novel emerging immune checkpoint molecule, was reported to express both on various kinds of immune cells and tumor cells. Many previous studies have investigated the prognostic significance of TIM-3 in cancer. However, the sample number from single study was limited and results remained controversial. <b>Methods:</b> We searched PubMed, Web of Science, and Embase databases for publications concerning TIM-3 ...[more]

PMID: 32850398

Similar Datasets

Project description:BackgroundEmerging evidence shows that microRNA-130 (miRNA-130) family may be useful as prognostic biomarkers in cancer. However, there is no confirmation in an independent validation study. The aim of this study was to summarize the prognostic value of miRNA-130 family (miRNA-130a and miRNA-130b) for survival in patients with cancer.MethodsThe pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to estimate the association strength between miRNA-130 family expression and prognosis. Kaplan-Meier plotters were used to verify the miRNA-130b expression and overall survival (OS).ResultsA total of 2141 patients with OS and 1159 patients with disease-free survival (DFS)/progression-free survival (PFS) were analyzed in evidence synthesis. For the miRNA-130a, the overall pooled effect size (HR) was HR 1.58 (95% CI: 1.21-2.06, P?<?0.001). Tissue and serum expression of miRNA-130a was significantly associated with the OS (HR?=?1.54, 95% CI: 1.11-2.14, P?=?0.009; HR?=?1.65, 95% CI: 1.14-2.38, P?=?0.008), and in gastric cancer (HR?=?1.81, 95% CI: 1.34-2.45, P?<?0.001). For the miRNA-13b, a statistical correlation was observed between high miRNA-130b expression and poor OS in patients with cancer (HR?=?1.95, 95% CI: 1.47-2.59, P?<?0.001), especially in tissue sample (HR?=?2.01, 95% CI: 1.39-2.91, P?<?0.001), Asian (HR?=?2.55, 95% Cl: 1.77-3.69, P?<?0.001) and hepatocellular carcinoma (HR?=?1.87, 95% CI: 1.23-2.85, P?=?0.004). The expression of miRNA-130b was significantly correlated with DFS/PFS (HR?=?1.53, 95% CI: 1.31-1.77, P?<?0.001), in tissue (HR?=?1.98, 95% CI: 1.50-2.62, P?<?0.001) and serum (HR?=?1.37, 95% CI: 1.15-1.64, P?<?0.001), especially in HCC (HR?=?1.98, 95% CI: 1.50, 2.62, P?<?0.001). In database test, a significant correlation between high miRNA-130b expression and poor OS for HCC patients was observed (HR?=?1.55, 95% CI: 1.01, 2.35, P?=?0.0045).ConclusionThe high expression of miRNA-130 family might predict poor prognosis in cancer patients. Prospectively, combining miRNA-130a and miRNA-130b may be considered as powerful prognostic predictor for clinical application.

Dataset Information

Prognostic Values of TIM-3 Expression in Patients With Solid Tumors: A Meta-Analysis and Database Evaluation.

Publications

Prognostic Values of TIM-3 Expression in Patients With Solid Tumors: A Meta-Analysis and Database Evaluation.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets